Anti-Calicheamicin payload antibody in PK study in ADC drug development

Anti-calicheamicin antibodies are critical in pharmacokinetic (PK) studies for accurately measuring the levels of calicheamicin and its conjugates in biological samples. Calicheamicin is a highly potent cytotoxic antibiotic used as a payload in antibody-drug conjugates (ADCs) for targeted cancer therapy. Due to its ability to cause double-stranded DNA breaks, calicheamicin is extremely effective at inducing cell death in tumor cells.

**Product list of GeneMedi's anti-Calicheamicin antibody**
Cat No.	Product Description	Fc	Products Information
GTU-Bios-Calicheamicin-Ab	Anti-Calicheamicin-monoclonal-antibody (mAb)	hFc/mFc	Details

All Payloads of ADCs

Application

Competitive immunoassay validation (CompetitiveELISA) and other Immunoassay,
PK & PD assay for MMAE payload of Antibody-drug Conjugate (ADC)

Highlight:

Purity: ≥95% (SDS-PAGE)
High affinityand specificity validated
High sensitivity verified by ADCs binding assay

Application
Technical Resource

Why Use Anti-Calicheamicin Antibody in ADC drug development?

Specificity: Anti-calicheamicin antibodies are tailored to bind specifically to calicheamicin and its derivatives. This specificity is essential for accurately quantifying the levels of calicheamicin, distinguishing it from other components of the ADC and from other substances in the body.
Sensitivity: Given the high toxicity and potency of calicheamicin, these antibodies need to be sensitive enough to detect very low concentrations of the drug. This capability is crucial for monitoring therapeutic levels and potential toxicity, ensuring that the drug remains within a safe and effective range.
Understanding ADC Dynamics: Using anti-calicheamicin antibodies helps researchers track the stability of the calicheamicin-ADC conjugate, monitor the release of calicheamicin from the conjugate, and measure the levels of free and total drug. This information is vital for assessing how the drug is delivered to and acts upon cancer cells, as well as how it is cleared from the body.

How to use Anti-Calicheamicin Antibody in ADC drug development?

Development of Immunoassays: These antibodies are used to develop immunoassays, such as enzyme-linked immunosorbent assays (ELISA), that can quantitatively measure calicheamicin concentrations in biological matrices like blood, plasma, and possibly tissues. These assays are crucial for evaluating how calicheamicin is absorbed, distributed, metabolized, and excreted.
Sample Collection and Analysis: In a PK study, biological samples are collected at various time points following the administration of the calicheamicin-ADC. These samples are analyzed using the developed immunoassays that incorporate anti-calicheamicin antibodies to determine the concentration of both the conjugated and free calicheamicin.
Data Interpretation and Clinical Application: The data obtained from these assays provide detailed insights into the pharmacokinetic profile of calicheamicin. This information is critical for optimizing dosing schedules, minimizing toxic side effects, and improving the overall therapeutic efficacy of the ADC.

Utilizing anti-calicheamicin antibodies in PK studies is therefore fundamental for the successful development and clinical application of calicheamicin-based ADCs. These studies ensure that treatment regimens are based on precise, reliable pharmacokinetic data, leading to safer and more effective cancer therapies.